Clinical Trials
27
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)ā¢ Click on a phase to view related trials
News
bluebird bio Strengthens Leadership Team with Three Key Executive Appointments
bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.
Protein Therapeutics Market Surges to $400 Billion as 20 New Drugs Gain Approval in 2023
The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies.
Novartis's Oral MS Drug FTY720 Shows Promising Two-Year Efficacy Data, Potential 2010 Launch
ā¢ Novartis's experimental oral multiple sclerosis drug FTY720 (fingolimod) demonstrated significant reduction in disease relapses and progression over a two-year study period compared to placebo. ā¢ The lower 0.5mg dose showed comparable efficacy to higher doses with improved safety profile, leading Novartis to pursue regulatory approval for this dosage. ā¢ Novartis plans simultaneous FDA and EU submissions by end of 2009, with potential US market launch as early as 2010 pending expedited review.